Fundraising Fox
Kenaitx
Founded 2022 · 40 employees on LinkedIn · 2 known investors
Find your way into Kenaitx
Sign up to see every warm intro you have to Kenaitx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kenaitx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
Founders & leadership
Kenaitx was founded in 2022 by Howard Federoff.
HF
Howard FederoffScientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and ScienceHoward Federoff holds an MD and PhD from Albert Einstein College of Medicine and has held senior leadership roles in biotech and higher education with expertise in cell and gene therapy, cognitive biomarkers, and advanced biologics approaches to neurological disease. He is Scientific Co-Founder and Chief Medical Officer of Kenai Therapeutics, which develops cell therapies derived from induced pluripotent stem cells for neurodegenerative diseases.
Investors · 2
Frequently asked questions
- What does Kenaitx do?
- Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
- Who founded Kenaitx?
- Kenaitx was founded by Howard Federoff in 2022.
- Who are Kenaitx's investors?
- Kenaitx's investors include Cure Ventures, The Column Group.